<DOC>
	<DOCNO>NCT02481180</DOCNO>
	<brief_summary>The purpose study ass MTD , Pharmacokinetics preliminary efficacy T0001 Rheumatoid Arthritis .</brief_summary>
	<brief_title>Tolerance , Pharmacokinetics Preliminary Efficacy T0001 RA ( Rheumatoid Arthritis )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Age 1845 year old ; Diagnosed active RA ; DMARDs therapy must use least 28 day prior baseline ; If patient receive NSAIDs，current NSAIDs therapy must stable dose least 28 day prior baseline ; Patient patient 's legal representative able give write informed consent participation trial . Acute chronic infection , history active tuberculosis ; History diseases central nervous system , cardiovascular system , kidney , liver ( specify liver function index ) , digestive system , respiratory system , metabolism system ; Patients high risk infection ( current infectious disease , chronic infectious disease , history serious infectious disease ) ; Patients use 5 Unit dos tuberculin skin test positive ( 4872 hour scleroma reading≥5mm ) ; Patients currently , history , malignancy ; Patients lack understanding , communication collaboration , ca n't comply protocol ; Female patient breastfeed pregnant , childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>